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Papaya proteinase IV (PPIV) is not inhibited by chicken cystatin, or human cystatins A or C, unlike most other proteinases of the papain superfami- 
ly. The enzyme inactivates chicken cystatin and human cystatin C by limited proteolysis of the glycyl bond previously shown to be involved in 
the inhibitory inactivity of the cystatins, but has no action on cystatin A. Contamination of commercial crystalline papain with PPIV accounts 
for the limited proteolysis of cystatins by ‘papain’ reported previously. PPIV is slowly bound by human qmacroglobulin. The enzyme is irreversibly 
inactivated by E-64, and by peptidyl diazomethanes containing glycine in P, and a hydrophobic side-chain in P2. The reaction of PPIV with iodo- 
acetate is extremely slow. PPIV is inhibited by peptide aldehydes despite the presence of bulky sidechains in P,, suggesting that these reversible 
inhibitors do not bind as substrate analogues. 
Macroglobulin, c+; Cystatin; Compound E-64; Iodoacetate; Iodoacetamide; Papain; Peptide aldehyde; Peptidyl diazomethane 
1. INTRODUCTION 
Papaya proteinase IV (PPIV) was recently 
discovered to be a major component of the latex of the 
unripe papaya (Carica papaya) fruit [l]. The amino 
acid sequence shows the enzyme to be closely related to 
papain and other cysteine proteinases of papaya [2], 
but substitution of certain residues in the active site 
cleft confers narrow substrate specificity, largely con- 
fined to the cleavage of glycyl bonds [3]. PPIV 
resembles most other members of the papain super- 
family in being irreversibly inactivated by E-64 [l], but 
it is not inhibited by the protein inhibitor of cysteine 
proteinases, chicken cystatin [l]. Earlier work on the 
interaction of commercial papain with cystatins led to 
the discovery of proteolytic inactivation of these in- 
hibitors by cleavage of a glycyl bond near the N- 
terminus. At the time, this was attributed to the action 
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Abbreviations: CYZM. human cuz-macroglobulin; Boc, t-butyloxy- 
carbonyl; Bz, benzoyl; E-64, L-3-carboxy-2,3-tranepoxypropionyl- 
leucylamido(4-guanidino)butane; NHMec, 7-(4-methyl)coumaryl- 
amide; NHPhNO2, p-nitroanilide; PPIII, papaya proteinase III; 
PPIV, papaya proteinase IV; Z, benzyloxycarbonyl; I, total inhibitor 
concentration; Kicapp), apparent dissociation constant of enzyme and 
inhibitor in the presence of substrate; Ki, inhibition constant; kobs, 
apparent pseudo-first-order rate constant for inactivation; k2capp), ap- 
parent second-order ate constant for inactivation in the presence of 
substrate; kz, second-order ate constant for inactivation 
of an abnormal form of papain [4]. The purpose of the 
present paper is to provide an alternative explanation 
for this phenomenon, and to describe further aspects of 
the interaction of PPIV with protein and small- 
molecule inhibitors. 
2. EXPERIMENTAL 
2.1. Materials 
Proteins were prepared as previously described: PPIV and papain 
[1,2], chicken cystatin [4], human cystatin A (also called stefin A: [5]) 
[6] and recombinant human cystatin C [7]. Human LYZM was a gift 
from Dr J.S. Mort, Shriners Hospital for Crippled Children, Mon- 
treal, Canada. Papain (2 x tryst., cat. no. P3125) and leupeptin were 
purchased from Sigma. Boc-Val-Gly-CHNz, Z-Leu-Val-Gly-CHNz, 
Z-Leu-Gly-CHN2, Z-Met-Gly-CHN2, Z-Phe-Gly-CHNZ, Z-Gln-Gly- 
CHNz, Z-Leu-Gly-Gly-CHN2 and Z-Leu-Phe-Gly-CHN2 were syn- 
thesized by standard methods [8,9]. Z-Phe-Phe-CHN2 and Z-Phe- 
Ala-CHN2 were purchased from Bachem Feinchemikalien AC, 
Bubendorf, Switzerland. Chymostatin was titrated with papain which 
had previously been titrated with E-64 [lo]. Other compounds were 
as described previously [3]. 
2.2. Automated amino acid sequencing 
This was as described [4]. 
2.3. Radial immunodgfusion assay of PPIV 
Specific immunoglobulin G antibody against PPIV was incor- 
porated into agarose gel at lOOpg/ml for use in single radial im- 
munodiffusion analysis otherwise as described in [l]. Commercial 
papain was carboxymethylated [lo] before application to the im- 
munodiffusion plate, and its concentration was determined on the 
basis of A2so,1m, = 25.0. 
2.4. Treatment of cystatins with PPIV 
Chicken cystatin (2 mg) was incubated with 4 ,ug of PPIV in 3.0 ml 
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of 0.05 M sodium phosphate buffer, pH 7.8, containing 0.67 mM 
dithiothreitol for 30 min at 30°C. Recombinant human cystatin C 
(0.2 mg) was incubated with 0.2pg of PPIV in 0.1 ml of 0.1 M 
sodium phosphate buffer, pH 6.5, containing 1 mM dithiothreitol 
and 1 mM EDTA for 60 min at 37°C. The modified protein was then 
separated by agarose gel electrophoresis [4], and blotted onto a 
polyvinylidene difluoride membrane for amino acid sequencing [111. 
Human cystatin A (1.2 mg) was incubated with PPIV (96rg) in 
1.0 ml of 50 mM sodium acetate buffer, pH 5.0, containing 2 mM 
dithiothreitol, for 8 h at 22°C. 
2.5. Interaction with CWM 
Papain or PPIV (430 pmol) was activated in 100~1 of 50 mM 
sodium phosphate, 1 mM EDTA, 2 mM cysteine, pH 6.5, for 30 min 
at 30°C. LY~M (1.2 nmol) was then added and the mixture was in- 
cubated for 15, 120 or 240 min at 30°C before application to a TSK- 
G 2000SW (LKB) gel chromatography column (7.5 x 600 mm) which 
had been equilibrated in 50 mM Tris/HCl, 0.5 M NaCl, 0.1% Brij 35 
in 20% glycerol, pH 7.5. Eluted fractions (0.5 ml) were assayed with 
Bz-Arg-NHPhNOr (for papain) or Boc-Ala-Ala-Gly-NHPhNOr (for 
PPIV). The activated enzymes, and curM, were also run individually 
on the column. 
2.6. Determination of kinetic parameters 
Molar concentrations of PPIV, papain and cystatins were deter- 
mined by stoichiometric titration [3]. Continuous rate assays with 
Boc-Ala-Ala-Gly-NHMec (50 PM) as substrate for PPIV or Z-Phe- 
Arg-NHMec (10/M) for papain, in 100 mM sodium phosphate, 
1 mM EDTA, 0.005% Brij 35, 2 or 4 mM cysteine, pH 6.8, 3O”C, 
were used to analyse the kinetics of reversible inhibition and irreversi- 
ble inactivation. For the determination of Ki(appr the rate of substrate 
hydrolysis in the absence of inhibitor was recorded, after which in- 
hibitor was added in a negligible volume and the new steady state was 
monitored. Non-linear regression analysis of the replot of fractional 
activity vs I (Enzfitter, Elsevier-Biosoft, Cambridge, England) gave 
Kr(app). Rate constants for inactivation were found by non-linear 
regression analysis of the apparent pseudo-first-order curves of inac- 
tivation utilizing the FLUSYS software package [12], giving kobs. 
k2caPP) was calculated as k&I. Ki and k2 were then found by the stan- 
dard correction for the effect of competition by substrate. 
3. RESULTS AND DISCUSSION 
3.1. Lack of inhibition of PPIV by cystatins 
There was no detectable inhibition of PPIV by 
human cystatin A (152 nM) or recombinant human 
cystatin C (1 nM). The lack of inhibition of PPIV by 
chicken cystatin has been reported earlier [l]. PPIV is 
one of the few plant cysteine proteinases that are 
scarcely inhibited by chicken cystatin [l], others being 
stem bromelain [13] and fruit bromelain [14]. 
3.2. Proteolytic modification of cystatins 
Automated amino acid sequencing of chicken 
cystatin modified by PPIV, and re-isolated by FPLC 
[4], showed the single sequence: Ala-Pro-Val-Pro-Val- 
Asp-, revealing that cleavage had occurred only at the 
Gly’-Ala” position. Recombinant human cystatin C 
was likewise found to be modified by the cleavage of 
the homologous Gly”-Gly” bond, the detected se- 
quence being Gly-Pro-Met-Asp-Ala-. In contrast, in- 
cubation of human cystatin A with PPIV did not result 
in the appearance of any new chromatographic com- 
ponents or N-terminal sequence; this is attributable to 
the presence of Pro in the P2 position relative to the 
homologous Gly” [ 151, which is not accepted by PPIV 
[31. 
Cleavage of the Gly’-bond of chicken cystatin and 
the Gly”-bond of cystatin C were previously seen with 
a commercial papain preparation [4]. Failure of the 
cystatins to inhibit PPIV is apparently not due to the 
rapid degradation seen with chicken cystatin and 
cystatin C, because cystatin A, which is also not in- 
hibitory for PPIV was not a substrate for the enzyme. 
Presumably, the restricted active site cleft of PPIV [3] 
will not accommodate the inhibitory ‘wedge’ [16] of the 
cystatins. 
3.3. Presence of PPIV in commercial papain 
The assay of commercial papain (Sigma) for PPIV 
by single radial immunodiffusion analysis showed the 
presence of PPIV at a level of 2.96 f 0.15% (w/w; 
mean f SE, n = 6). 
3.4. Interaction with 44 
The percentages of total PPIV associated with LYZM 
after various incubation times (see section 2) were 0% 
(0 min), 25% (15 min), 40% (120 min), and 50% 
(240 min). Corresponding values for papain were 0% 
(0 min) and 80% (15 min). We conclude that PPIV is 
bound by CYZM, like the great majority of endopep- 
tidases, but at least one order of magnitude more slow- 
ly than papain. 
3.5. Irreversible inactivation by active-site-directed 
reagents 
The second order rate constants for inactivation of 
PPIV by iodoacetate, iodoacetamide, E-64 and a series 
of peptidyl diazomethanes are shown in table 1. The 
very low rate of inactivation of PPIV by iodoacetate is 
Table 1 
Rate constants for the inactivation of PPIV 
Inactivator k2 (M-‘+s-‘) 
PPIV Papain 
Iodoacetate 2.2 1000 
Iodoacetamide 0.5 46 
E-64 58000 1160000 
Z-Phe-Phe-CHNr <lO 5500 
Z-Phe-Ala-CHNr 60 43000 
Z-Gln-Gly-CHN2 100 50 
Boc-Val-Gly-CHNr 5000 12ooo 
Z-Leu-Gly-CHN2 5500 1600 
Z-Met-Gly-CHNr 5500 1700 
Z-Phe-Gly-CHN2 14500 12OGu 
Z-Leu-Gly-Gly-CHN2 <50 <50 
Z-Leu-Phe-Gly-CHN2 630000 62000 
Z-Leu-Val-Gly-CHNr 3500000 460000 
Rate constants were determined as described in section 2 at pH 6.8 
and 30°C 
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of a similar order to that of an enzyme from ger- 
minating bean cotyledons 1171, and stem bromelain 
also reacts very slowly [18]. The structural basis for the 
great differences in reactivity of the catalytic site cys- 
teine in homologous proteinases has yet to be ex- 
plained. 
The rate constant for inactivation of PPIV by E-64 
was previously estimated to be 15 300 M-’ * s-l [ 11, but 
the value of 58 000 M-r - s-l now obtained by use of the 
sensitive fluorimetric substrate is likely to be more ac- 
curate. The inhibitor probably binds with the leucine 
sidechain in the S2 subsite (in the terminology of [19]), 
leaving the & subsite essentially unoccupied, as is the 
case with papain [20]. 
The data for the peptidyl ~~orneth~e i~ibitors 
(table 1) reflect the primary specificity of PPIV for Gly 
in Si [3], but also reveal a strong preference for a 
hydrophobic side-chain in SZ; Leu, Val, Met and Phe 
all being preferred over Gln in Pz. This is a preference 
also seen with papain. The occupation of the S3 binding 
pocket of PPIV by Leu (and possibly S4 by the Z 
group) in Z-Leu-Phe-Gly-CHN2 and Z-Leu-Val-Gly- 
CHN2 led to further large increases in k2 of over one 
and almost three orders of magnitude, respectively, 
when compared with corresponding dipeptide 
derivatives. The effects were smaller with papain. The 
structure of the fastest-reacting inhibitor of PPIV, Z- 
Leu-Val-Gly-CHN2, had been modelled on the cleavage 
site of cystatin C [21]. The increase in k2 afforded by 
the extra amino acid residue indicates that PPIV, like 
papain [ 191, has an extended binding site. Even so, no 
significant inhibition of either PPIV or papain was seen 
with Z-Leu-Gly-Gly-CHN2, which emphasises the im- 
portance of the hydrophobic side-chain in SZ. 
3.6. Reversible inhibition 
The inhibition of PPIV by two peptide aldehydes was 
studied. The Ki with leupeptin was found to be 20 nM, 
and with chymostatin 53 nM. These interactions are 
weaker than those of the aldehydes with papain 
(1.6 nM and 0.73 nM, respectively) but nevertheless 
surprisingly strong in view of the presence of arginine 
and phenylalanine sidechains in what could correspond 
to the Pi position. The possibility has to be considered 
that the aldehydes do not bind in a substrate-like way, 
however. 
In conclusion, our results show that the earlier fin- 
ding of cleavage of crucial glycyl bonds in two type 2 
cystatins by ‘papain’ can be explained by the presence 
of PPIV in the commercial enzyme preparation. They 
also confirm the primary specificity of PPIV for glycyl 
bonds, and indicate that subsites SZ and S3 preferential- 
ly accommodate hydrophobic sidechains. 
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